Jazz CEO has 4,835 shares withheld for taxes
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc reported a routine insider transaction by its President & CEO, Renee D. Gala. On June 30, 2026, 4,835 ordinary shares were withheld at $237.72 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. This was a tax-withholding disposition, not an open-market sale. Following the transaction, Gala directly holds 147,361 ordinary shares of Jazz Pharmaceuticals.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Ordinary Shares | 4,835 | $237.72 | $1.15M |
Footnotes (1)
- F1. Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Key Figures
Key Terms
tax-withholding disposition financial
restricted stock units financial
Form 4 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Jazz Pharmaceuticals (JAZZ) disclose for its CEO?
Was the Jazz Pharmaceuticals (JAZZ) CEO’s Form 4 transaction an open-market sale?
What does transaction code F mean in the Jazz Pharmaceuticals (JAZZ) CEO’s Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.